Search results: (10000)
News Does adding statins to DOACs reduce the risk of major bleeding in patients with non-valvular atrial fibrillation?
A large retrospective study, the results of which were recently published, investigated to what extent the concurrent administration of statins is associated with a lower risk of major bleeding, including intracranial and gastrointestinal bleeding, in patients with non-valvular atrial fibrillation taking direct oral anticoagulants (DOACs).
News Efficacy of Conventional and Intensified Lifestyle Interventions in Individuals with Prediabetes According to Risk Level
Lifestyle changes can prevent the development of type 2 diabetes in individuals with prediabetes, but according to current findings, these measures fail for a significant portion of study participants. In the Diabetes Prevention Program (DPP) study, one in five patients in the lifestyle intervention group developed type 2 diabetes within 4 years. However, there are individuals with prediabetes who do not develop diabetes without lifestyle intervention even after 11 years of follow-up. This indicates the need to create more precisely stratified intervention strategies based on the identification of high-risk (HR) and low-risk (LR) individuals with prediabetes. This is precisely the focus of a recently published study by German authors.
News Metformin with Extended Release in the Treatment of Prediabetes
The benefit of metformin in preventing the development of diabetes in people with prediabetes has been demonstrated in clinical studies. However, these studies evaluated immediate-release metformin, not its extended-release form (XR). Therefore, the results of an observational study conducted at Polish and Hungarian centers, which examined the efficacy and safety of metformin XR in patients with prediabetes, are important in this context. It is also necessary to add that in our country, no drug containing this active substance has yet received an approved indication for the therapy of patients with prediabetes.
News The Future of Multiple Sclerosis – Time for a Change in Classification?
What are the latest findings on the etiopathogenesis of multiple sclerosis? Are they reflected in the current classification? And what will future therapy look like?
News Recent findings on the role and potential of L. reuteri in the therapy of GIT diseases
Probiotics contain bacterial or yeast strains similar to beneficial types naturally occurring in the human gastrointestinal tract. Their role in the therapy of gastrointestinal diseases has been extensively researched, demonstrating significant effects on a number of nosological units. One modality of probiotic therapy involves the administration of the bacteria L. reuteri, specifically the laboratory-modified strain DSM 17938.
News Lorlatinib in a Patient with Meningeal Carcinomatosis – Case Report
The prognosis of patients with meningeal carcinomatosis is unfavorable. The following case report demonstrates how a targeted mechanism of action and optimal drug penetration into the central nervous system (CNS) can not only quickly relieve patients from neurological problems associated with meningeal infiltration, but also prolong their survival.
News Substitution Treatment of von Willebrand Disease with vWF and FVIII Concentrates
Recently published recommendations from Poland regarding the diagnosis and treatment of von Willebrand disease (vWD) provide a comprehensive summary of the current approach to substitution therapy using concentrates containing von Willebrand factor (vWF) and coagulation factor VIII (FVIII), administered primarily during bleeding or surgical procedures.
News Estimated Worldwide Prevalence of Population with AAT Deficiency with MZ Alleles
Alpha-1-antitrypsin deficiency (AATD) with the MZ genotype was until recently associated with negligible or low risk for lung and liver tissue damage. However, growing evidence suggests that carriers of MZ alleles are at increased risk of organ damage when exposed to tobacco smoke, polluted air, or hepatotoxic substances. Moreover, according to a global epidemiological study, the prevalence of the MZ genotype is very common, especially among Caucasians in Europe and other continents.
News Repeated Episodes of Respiratory Failure Due to Undiagnosed AAT Deficiency – Case Report
The case report from authors in Naples shows that alpha-1-antitrypsin deficiency (AATD) should be considered when respiratory symptoms occur at any age. It also illustrates the diagnostic procedure in such cases and confirms the effectiveness of subsequently initiated therapy.
News Persistent Symptom Control with s.c. Supplementation of C1 Inhibitor in Prophylactic Treatment of HAE
The open-label extension of the COMPACT study with subcutaneous C1 inhibitor in the prophylaxis of hereditary angioedema (HAE) has brought fresh results, shedding light on the treatment's impact on the frequency of attacks and reducing the need for rescue medication.
News Inhibitor of Activated Factor XII Garadacimab in Prophylaxis of HAE Attacks
Hereditary angioedema (HAE) is an autosomal dominant inherited disease characterized by a deficiency of C1 inhibitor. This condition leads to excessive production of bradykinin, which is responsible for the development of soft tissue edema. Garadacimab represents a human antibody, the first of its class, aimed at inhibiting activated factor XII, a key initiator of bradykinin formation. The phase II study presented below, whose results were recently published, evaluated the efficacy and safety of this innovative HAE therapy.
News Good news for sleep in patients with axial spondyloarthritis – ixekizumab effectively reduces night-time back pain
The targeted treatment of axial spondyloarthritis currently relies on the anti-inflammatory effects of tumor necrosis factor (TNF) inhibitors, interleukin IL-17 inhibitors, and Janus kinase (JAK) inhibitors. Besides the objective efficacy of these targeted treatments, it is crucial to describe their influence on subjective symptoms for decision-making in clinical practice. The evaluation of the analgesic effect of ixekizumab (IXE) was provided by the randomized controlled trial COAST-V.
News To what extent can improvement of nutritional status through parenteral nutrition affect the results of oncological treatment?
Just like cancer patients and their caregivers, doctors often overlook the risk of malnutrition. Good nutrition can be a predictor of survival in patients with malignancies.
News Does SGLT2 Inhibitor Administration Benefit Diabetics with Low Cardiorenal Risk?
There is growing evidence of the cardiorenal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, also known as gliflozins), which were developed as antihyperglycemic drugs for the treatment of type 2 diabetes. These antidiabetic medications are recommended for patients with heart or renal disease or at high risk of these complications. However, is it worthwhile to consider their use in diabetics as part of long-term primary cardiorenal prevention? Israeli authors sought the answer to this question.
News 6 Possible Benefits of Adding Empagliflozin to Metformin
Currently, there is intense discussion about the advantages of sodium-glucose co-transporter 2 inhibitors (SGLT2i, also known as gliflozins) in terms of their cardio and nephroprotective properties. Below, we summarize the proven beneficial effects specifically associated with adding empagliflozin to metformin and mention the indications for empagliflozin, which are reimbursed.